MD Anderson, Intrexon, and Ziopharm announce sublicensing agreement with the University of Minnesota

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

MD ANDERSON CANCER CENTER, Intrexon Corporation and Ziopharm Oncology announced a sublicensing agreement for intellectual property developed at the University of Minnesota for the development of non-viral adoptive cellular cancer immunotherapies.

Researchers at the University of Minnesota have explored the design and clinical investigation of novel chimeric antigen receptor T cell therapies using non-viral gene integration platforms. MD Anderson has built on this technology to deliver patient-derived T cells, as well as innovative approaches to generating products for universal off-the-shelf applications. The agreement will also use Intrexon’s technology suite and Ziopharm’s RheoSwitch Therapeutic System interleukin-12 modules.

The work continues in conjunction with MD Anderson’s Moon Shots Program. Clinical trials using non-viral adoptive cellular therapies are either under way or planned for the specific cancers in the program.

Under the terms of the agreement, MD Anderson will receive consideration of $100 million; $50 million from each Intrexon and Ziopharm, payable in shares of their respective common stock, as well as a commitment of $15 to $20 million annually over three years for researching and developing the technologies.

The parties will enter into additional collaboration and technology transfer agreements to accelerate technology and clinical development.

YOU MAY BE INTERESTED IN

Just consider for a minute if this was the first year of running your lab, if you were on the job market as a physician or scientist right now, if you were a resident contemplating a career in cancer research after fellowship, if you were a graduate student or postdoc, if you were an undergraduate or a technician who was looking toward graduate school.
The immune system can be a powerful tool to control cancer. Immune cells within our body detect cancer cells and release payloads that kill them. Transformative science in the last decade has led to the development of therapies that enhance the ability of our immune cells to carry out this function. These therapies, including checkpoint blockade and CAR-T cells, have been lifesaving for many patients that before had untreatable cancer. But, sadly, a majority of patients with advanced solid tumors still succumb to their disease. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login